Mini-HTA for irreversible electroporation (IRE) for treatment of liver metastases was prepared by Oslo University Hospital

12

Oct 2017

Irreversible electroporation (IRE) is a new minimally invasive method for the ablation of tumors. Unlike the current leading methods of thermal ablation, such as radiofrequency ablation and cryoablation, IRE based on non-thermal electric energy. There is currently one commercially available device for IRE - NanoKnife® System (AngioDynamics, USA).

Currently, this method is not used in Norway. Additionally, in Nordic countries, this treatment is offered in Uppsala, Sweden and at Rigshospitalet in Copenhagen, Denmark.

At the beginning of September, a report with results of mini-HTA of irreversible electroporation for treatment of liver metastases that was performed by Oslo University Hospital was published at the Norwegian national database.

The purpose of the assessment was to introduce a new method and evaluate this technology in relation to efficacy, safety, associated costs and ethics in patients who have inoperable primary and secondary malignant liver tumors (liver metastases (colorectal and others), hepatocellular carcinoma, cholangiocarcinoma) and not suitable for other ablation treatment. A systematic literature search for systematic literature reviews, clinical trials, clinical guidelines and health technology assessments was performed.

In accordance to the report, there are no RCTs, cohort and comparative studies for IRE. The evidence is limited to a single-center case series studies. However, available evidence was found suitable to confirm that method is safe and feasible. Additionally, it was stated that results from identified studies are transferable to clinical practice. The expected number of patients for IRE procedure is about 15 patients.

The conclusion of mini-HTA stated that IRE should be included as part of the routine clinical practice in the hospital. The method will be continuously monitored through the quality registry, and all data will be incorporated into IRE international registry.

See full report in Norwegian here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more